Navigation Links
Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors

BOTHELL, Wash., Nov. 1, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that it has appointed A. Bruce Montgomery, M.D., to the company's board of directors.

Dr. Montgomery, 57, served as founder and chief executive officer of Corus Pharmaceuticals from 2001 through its acquisition in 2006 by Gilead Sciences. While at Gilead, he served as Senior Vice President and Head of Respiratory Therapeutics where he successfully led the approval of Cayston (aztreonam) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. He previously held positions in clinical development with PathoGenesis and Genentech. Dr. Montgomery recently served on the board of directors for Zymogenetics and is a trustee of the Washington State Life Sciences Fund.

"Bruce brings a wealth of global pharmaceutical and biotechnology industry experience to the Alder board including his involvement with a number of drug approvals," said Randall Schatzman, president and chief executive officer of Alder Biopharmaceuticals. "We look forward to his contributions as Alder continues to grow its pipeline of clinical assets and move ALD518 through clinical studies in cancer, cancer anemia and cancer supportive care."

Dr. Montgomery received a bachelor's degree in chemistry and a doctorate from University of Washington. He completed postgraduate training at University of Washington and University of California, San Francisco.

About Alder BiopharmaceuticalsAlder Biopharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. In addition to Bristol-Myers Squibb, partners include Merck (Schering-Plough), Seattle Genetics and Genmab. For more information, visit Media Contact: Ian Stone or David SchullRusso PartnersTel: +1

SOURCE Alder Biopharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FreshFx Recognized for use in the Scalder as a Solution to the Yield/Pathogen Reduction Dilemma
2. Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases
3. Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis
4. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
5. Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation
6. Herbruck Alder to Convene Summit on the New Healthcare Reform Law
7. Perrigo Confirms Filing for Clobetasol Shampoo and Announcement of Patent Infringement Lawsuit by Galderma
8. FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15
9. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
Post Your Comments:
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Allergan plc ... an agreement with the New York State ... 2 of the Sherman Act, and other statutes with the ... in February 2014, to cease marketing and selling the now ... of settlement, Allergan admits no liability, has released its counterclaims ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... NEW YORK , November 25, 2015 ... global market of self-monitoring blood glucose devices was valued ... to grow with a CAGR of 5.7% during 2015 ... increasing geriatric population and increasing prevalence of diabetes. In ... about diabetes care is also contributing to the growth ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at the Ageless ... treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, ... without the need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, ... country to celebrate their sobriety and show through pictures what a positive difference ... photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 23rd ... Tri Lite’s personal heating products business. Cozy Products explains what this means ... that fit in well with the Cozy Products business model: to sell personal heaters ...
(Date:11/25/2015)... MI (PRWEB) , ... November 25, 2015 , ... In ... Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy ... medical and surgical intensive care units (totaling 30 beds) from May 2014 through October ...
(Date:11/25/2015)... PA (PRWEB) , ... November 25, 2015 , ... ... treat my cancer, I found that regular bras were incredibly uncomfortable," said an ... developed this specialized bra." , She developed the patent-pending RECOVERY BRA for added ...
Breaking Medicine News(10 mins):